Modafinil
Modafinil, Provigil (modafinil) is a small molecule pharmaceutical. Modafinil was first approved as Provigil on 1998-12-24. It is used to treat attention deficit disorder with hyperactivity, fatigue, narcolepsy, and obstructive sleep apnea in the USA. It is known to target sodium-dependent dopamine transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Provigil (generic drugs available since 2012-09-26)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
205 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | D005221 | HP_0012378 | R53.83 | 3 | 10 | 7 | 4 | 3 | 25 |
| Healthy volunteers/patients | — | — | — | 11 | 1 | — | 1 | 4 | 16 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 3 | 4 | — | 5 | 1 | 12 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | 7 | 3 | 1 | 12 |
| Sleepiness | D000077260 | — | R40.0 | — | 1 | 4 | 2 | 1 | 7 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 2 | — | 2 | 1 | 5 |
| Sleep wake disorders | D012893 | — | G47 | — | 1 | 1 | 1 | 1 | 4 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | — | — | 3 | — | 4 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 2 | 1 | 1 | 4 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 2 | 1 | — | 4 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 4 | 15 | 1 | — | 3 | 22 |
| Narcolepsy | D009290 | HP_0030050 | G47.4 | 1 | 3 | 11 | — | 4 | 19 |
| Neoplasms | D009369 | — | C80 | 1 | 3 | 3 | — | 1 | 8 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | — | 2 | 5 | — | 2 | 8 |
| Depression | D003863 | — | F33.9 | — | 1 | 4 | — | 1 | 6 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | 1 | — | 2 | — | 1 | 4 |
| Cataplexy | D002385 | HP_0002524 | — | — | — | 2 | — | 1 | 3 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | 2 | — | — | 3 |
| Circadian rhythm sleep disorders | D020178 | — | G47.2 | — | — | 2 | — | 1 | 3 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | 2 | — | 1 | 3 |
Show 18 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 3 | — | — | 2 | 5 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | 1 | — | — | 1 | 4 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | 3 | — | — | — | 4 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 2 | — | — | 1 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | 2 | 3 |
| Glioma | D005910 | EFO_0000520 | — | — | 2 | — | — | — | 2 |
| Head and neck neoplasms | D006258 | — | — | 2 | 2 | — | — | — | 2 |
| Sleep deprivation | D012892 | — | F51.12 | 1 | 1 | — | — | — | 2 |
| Central nervous system neoplasms | D016543 | — | — | — | 1 | — | — | 1 | 2 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | 1 | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Orthostatic hypotension | D007024 | — | I95.1 | 1 | — | — | — | — | 1 |
| Humans | D006801 | — | STY/T016 | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 1 | — | — | — | — | 1 |
| Cannabis | D002188 | — | — | 1 | — | — | — | — | 1 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | — | 1 | — | — | — | — | 1 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 1 | — | — | — | — | 1 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | — | — | — | 1 | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | — | — | 1 | 1 |
| Glucose metabolism disorders | D044882 | — | — | — | — | — | — | 1 | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | — | — | 1 | 1 |
| B-cell lymphoma | D016393 | — | — | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Critical illness | D016638 | — | — | — | — | — | — | 1 | 1 |
| Creativity | D003405 | — | — | — | — | — | — | 1 | 1 |
| Motivation | D009042 | — | — | — | — | — | — | 1 | 1 |
| Reward | D012201 | — | — | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Modafinil |
| INN | modafinil |
| Description | 2-[(diphenylmethyl)sulfinyl]acetamide is a sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group. It is a sulfoxide and a monocarboxylic acid amide. |
| Classification | Small molecule |
| Drug class | CNS stimulanteugeroic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 112111-43-0 |
| RxCUI | 30125 |
| ChEMBL ID | CHEMBL1373 |
| ChEBI ID | 77585 |
| PubChem CID | 4236 |
| DrugBank | DB00745 |
| UNII ID | R3UK8X3U3D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC6A3
SLC6A3
Organism
Homo sapiens
Gene name
SLC6A3
Gene synonyms
DAT1
NCBI Gene ID
Protein name
sodium-dependent dopamine transporter
Protein synonyms
DA transporter, dopamine transporter 1, solute carrier family 6 (neurotransmitter transporter), member 3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, Solute carrier family 6 member 3
Uniprot ID
Mouse ortholog
Slc6a3 (13162)
sodium-dependent dopamine transporter (Q9R1I2)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Provigil – Cephalon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Modafinil
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,612 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,086 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use